CNS Specialty Growth Aytu BioPharma focuses on innovative medicines for complex CNS diseases, presenting a sales opportunity to partner with neurology clinics, psychiatry practices, and specialized CNS centers seeking advanced therapies for treatment-resistant conditions.

Exxua Commercialization Recent launch of Exxua (gepirone) extended-release tablets for major depressive disorder signals a need for market access, key account management, and payer strategy collaboration across hospitals, IPAs, and specialty pharmacies.

Strategic Partnerships Collaborations with Fabre-Kramer Pharmaceuticals and active participation in investor conferences indicate a network-driven go-to-market approach; leverage co-promotion, distribution channels, and KOL engagement to accelerate uptake.

Resource Leverage With 51-200 employees and a growing revenue profile, there are opportunities to upsell ancillary CNS solutions, patient support programs, and digital patient engagement tools to healthcare providers and payers.

Market Visibility Publicly announced expansions and investor-focused events create brand awareness; use this momentum to target specialty pharmacies, behavioral health networks, and academic centers involved in CNS research and depression treatment.